Biotech

All Articles

Neurocrine's KarXT opponent attacks in phase 2-- but only at reduced dosage

.Neurocrine Biosciences has accomplished its own hoped-for account in a phase 2 mental illness trial...

Vaderis' uncommon capillary condition medicine reduces nosebleeds

.Vaderis Therapies' objective to cultivate the initial drug aimed exclusively at a certain unusual c...

Navigator brings up $100M to build brand new autoimmune pipe

.Sat nav Medicines has actually furnished on its own along with $100 thousand in series A funds as t...

Duality finds cash for ADC tests as IPO wave spreads to Asia

.China's Duplicity Biotherapeutics has filed (PDF) paperwork for a Hong Kong IPO, seeking a hidden t...

YolTech markets China civil rights to genetics editing therapy for $29M

.4 months after Mandarin gene editing company YolTech Therapeutics took its cholesterol disease-focu...

Addex stock climbs after Indivior provides to $300M for material

.Indivior is actually picking up a small particle allosteric modulator made to deal with drug usage ...

Molecular Partners tweaks AML trial over 'suboptimal direct exposure'

.Molecular Partners has actually determined "suboptimal direct exposure" to its own tetra-specific T...

Despite combined market, an equity capital rebirth could be coming in Europe: PitchBook

.While the biotech assets scene in Europe has actually slowed rather observing a COVID-19 funding bo...

8 months after a $213M fundraise, gene publisher Volume helps make cuts

.After raising $213 million in 2023-- among the year's most extensive exclusive biotech shots-- Volu...

BioMarin builds officer group with biotech veterinarians-- Chutes &amp Ladders

.Invite to this week's Chutes &amp Ladders, our summary of substantial leadership hirings, shootings...